176 related articles for article (PubMed ID: 19272638)
1. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Hayes MP; Douglas W; Ellenson LH
Gynecol Oncol; 2009 Jun; 113(3):370-3. PubMed ID: 19272638
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
[TBL] [Abstract][Full Text] [Related]
5. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Black JD; Lopez S; Cocco E; Bellone S; Altwerger G; Schwab CL; English DP; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2015 Sep; 113(7):1020-6. PubMed ID: 26325104
[TBL] [Abstract][Full Text] [Related]
7. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
[TBL] [Abstract][Full Text] [Related]
8. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
[TBL] [Abstract][Full Text] [Related]
9. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
Black JD; English DP; Roque DM; Santin AD
Womens Health (Lond); 2014 Jan; 10(1):45-57. PubMed ID: 24328598
[TBL] [Abstract][Full Text] [Related]
11. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Bashir S; Jiang G; Joshi A; Miller C; Matrai C; Yemelyanova A; Caputo TA; Holcomb KM; Ellenson LH; Gupta D
Int J Gynecol Cancer; 2014 Sep; 24(7):1262-7. PubMed ID: 25078343
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.
Jones NL; Xiu J; Reddy SK; Burke WM; Tergas AI; Wright JD; Hou JY
Gynecol Oncol; 2015 Sep; 138(3):620-6. PubMed ID: 26123645
[TBL] [Abstract][Full Text] [Related]
14. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
15. Early stage uterine serous carcinoma: management updates and genomic advances.
Fader AN; Santin AD; Gehrig PA
Gynecol Oncol; 2013 Apr; 129(1):244-50. PubMed ID: 23321062
[TBL] [Abstract][Full Text] [Related]
16. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
17. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
18. Early uterine serous carcinoma: clonal origin of extrauterine disease.
Baergen RN; Warren CD; Isacson C; Ellenson LH
Int J Gynecol Pathol; 2001 Jul; 20(3):214-9. PubMed ID: 11444195
[TBL] [Abstract][Full Text] [Related]
19. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
20. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
Saglam O; Husain S; Toruner G
Int J Gynecol Pathol; 2013 Sep; 32(5):493-500. PubMed ID: 23896716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]